Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01513733 · ClinicalTrials.gov registry record · Phase 1
The CATCH Prostate Cancer Trial: Cabazitaxel And Tasquinimod in Men With Prostate Cancer
A Phase 1 study, sponsored by Andrew J. Armstrong, MD.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT01513733 is a Phase 1 study that has completed, run by Andrew J. Armstrong, MD. The registered enrollment target is 25 participants.
The verdict
NCT01513733, a Phase 1 study, has completed, sponsored by Andrew J. Armstrong, MD.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
The standard of care for men with metastatic CRPC in 2010 following progression on docetaxel is cabazitaxel or abiraterone acetate/prednisone. Based on results from two other studies, cabazitaxel and prednisone has become a standard second line chemotherapy regimen and becomes the backbone upon which to improve upon. Thus, the primary objective of this study is to determine the recommended dose of tasquinimod in combination with cabazitaxel and prednisone based on safety and tolerability in men with chemorefractory metastatic castration-resistant prostate cancer (CRPC).
Interventions
- DRUG tasquinimod
- DRUG tasquinimod 0.25 mg; 0.5 mg
- DRUG tasquinimod 0.25 mg; 0.5 mg; 1.0 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2012-01 |
| Est. Completion | 2016-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01513733
The ClinicalTrials.gov registry entry for NCT01513733 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Andrew J. Armstrong, MD, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which tasquinimod is the first listed.
NCT01513733 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01513733 about?
NCT01513733 is a clinical study titled "The CATCH Prostate Cancer Trial: Cabazitaxel And Tasquinimod in Men With Prostate Cancer". The standard of care for men with metastatic CRPC in 2010 following progression on docetaxel is cabazitaxel or abiraterone acetate/prednisone. Based on results from two other studies, cabazitaxel and prednisone has become a standard second line chemotherapy regimen and becomes the backbone upon whic...
What is the current status of trial NCT01513733?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2012-01. Estimated completion is 2016-06.
What interventions are being tested in trial NCT01513733?
The interventions under investigation include: tasquinimod (DRUG), tasquinimod 0.25 mg; 0.5 mg (DRUG), tasquinimod 0.25 mg; 0.5 mg; 1.0 mg (DRUG).
Who is sponsoring clinical trial NCT01513733?
This trial is sponsored by Andrew J. Armstrong, MD, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.